NCT01896921View on ClinicalTrials.gov

Switch to Maraviroc + Integrase Inhibitor

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
HIV
Interventions
DRUG

Switch to Maraviroc + Raltegravir or Dolutegravir

Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks

Trial Locations (1)

21201

University of Maryland, Institute of Human Virology, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT01896921 - Switch to Maraviroc + Integrase Inhibitor | Biotech Hunter | Biotech Hunter